Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells.

British journal of cancer - 3 Sept 2013

van Oosterwijk J G, van Ruler M A J H, Briaire-de Bruijn I H, Herpers B, Gelderblom H, van de Water B, Bovée J V M G

Abstract excerpt

BACKGROUND: Chondrosarcomas are malignant cartilage-forming tumours of bone. Because of their resistance to conventional chemotherapy and radiotherapy, currently no treatment strategies exist for unresectable and metastatic chondrosarcoma. Previously, PI3K/AKT/GSK3β and Src kinase pathways were s...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotics, Antineoplastic
Share to Chondrosarcoma
Share to Dasatinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glycogen Synthase Kinase 3

Share to Glycogen Synthase Kinase 3 beta

Share to MCF-7 Cells

Share to Proto-Oncogene Proteins c-fyn

Share to src-Family Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 23922104
DOI: 10.1038/bjc.2013.451
PMCID: PMC3778302

Genes

RTCA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23922104-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells.PMID 23922104Read ↗

Kinome Profiling of Chondrosarcoma Reveals Src-Pathway Activity and Dasatinib as Option for TreatmentSemantic proximity Read ↗

Molecular oncogenesis of chondrosarcoma: impact for targeted treatmentSemantic proximity Read ↗

Functional profiling of receptor tyrosine kinases and downstream signaling in human chondrosarcomas identifies pathways for rational targeted therapy.Semantic proximity Read ↗

Chondrosarcoma: An overview of clinical behavior, molecular mechanisms mediated drug resistance and potential therapeutic targetsSemantic proximity Read ↗

Clinical activity of mTOR inhibition in combination with cyclophosphamide in the treatment of recurrent unresectable chondrosarcomasSemantic proximity Read ↗

Trp53 and Rb1 deficiency in chondrocytes spontaneously develop chondrosarcoma by activation of YAP signalingSemantic proximity Read ↗

Novel therapeutic approaches in chondrosarcoma.Semantic proximity Read ↗

High-Throughput Drug Screening in Chondrosarcoma Cells Identifies Effective Antineoplastic Agents Independent of IDH Mutation.Semantic proximity Read ↗

New chondrosarcoma cell lines and mouse models to study the link between chondrogenesis and chemoresistance.Semantic proximity Read ↗

RNAi phenotype profiling of kinases identifies potential therapeutic targets in Ewing's sarcoma.Semantic proximity Read ↗

Src Family Kinases as Therapeutic Targets in Advanced Solid Tumors: What We Have Learned So FarSemantic proximity Read ↗

Therapeutic Targets and Emerging Treatments in Advanced Chondrosarcoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.